Clinical Trial Update: Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating Camu-Camu prebiotic with immune checkpoint inhibition in patients with advanced non-small cell lung cancer and melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Camu-Camu prebiotic
• Immune checkpoint inhibitor (unspecified)

Snippet

Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) | Conditions: NSCLC Stage IV, Melanoma Stage IV | Phase 1 | Status: COMPLETED